Artwork for podcast PeDRA Pearls
Points of Discussion: Should JAK Inhibitors be Considered for First-Line Therapy in the Treatment of AD in Children? Episode 3
31st January 2022 • PeDRA Pearls • Pediatric Dermatology Research Alliance
00:00:00 00:18:36

Share Episode

Shownotes

Identifying Research Gaps

In this final episode, the group discusses what research is still needed to better understand the risks and benefits of JAK inhibitors for the treatment of moderate-to-severe atopic dermatitis in children.

Links